Physician profile
Reena Varghese
NPI 1144929829
$1,048.80
in general payments reported to CMS, 2019-2025
11 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $93.70 · 2024: $86.68 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.67 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $142.52 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $74.99 | 2023 | Fycompa |
| Lundbeck LLC | $70.87 | 2024-2025 | Vyepti, Rexulti |
| Pfizer INC. | $52.51 | 2025 | |
| Medtronic, INC. | $34.83 | 2025 | Percept PC Brainsense |
| Neurocrine Biosciences, INC. | $34.83 | 2025 | |
| Grifols USA, LLC | $24.98 | 2024 | Gamunex-C |
| E.R. Squibb & Sons, L.L.C. | $21.83 | 2025 | Zeposia |
| Kyowa Kirin, INC. | $21.08 | 2024 | Nourianz |
| Eisai INC. | $20.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.